Hi Aussie,
"This would be a great opportunity for the company to release an announcement to the market. Unfortunately, I would only expect it to be mentioned in passing within a quarterly."
You raise an interesting point here, Aussie. If you recall, the US patent Allowance and Grant by the USPTO was announced to the market within the 2012 financial reporting period last year, on August 23rd and November 3rd, 2011 respectively...
23.08.2011: US Patent Office Allows Dermaportation Patent
03.11.2011: US Patent Granted
So, why was this significant piece of news for the company omitted from the Annual Report this year, covering all activities for this same period??? I highly doubt that was a simple oversight...
27.09.2012: Annual Report 2012
I suspect OBJ holders may soon be provided with the appropriate answer... and one we have long been waiting for... ;)
__________
02.11.2012: Bibliographic data of the European patent application
02.11.2012: Communication about intention to grant a European patent
02.11.2012: Druckexemplar / Approved Text
02.11.2012: Intention to grant
__________
28 February 2012: Appendix 4D 31 Dec 2011
"The Company received notification from the US Patent Office in August 2011 that its Dermaportation or powered technology device patent had been allowed. This has subsequently allowed the Company to gain considerable interest from major cosmetic groups for the Company’s new e-skin product range. The potential market exclusivity provided by the US patent has considerably strengthened market interest. Late in 2011, the Company reported that the previously announced Strategic Alliance program with one of the world's leading Consumer Products companies had further progressed following successful technical evaluations. In October, the Company learned that the FMCG company was seeking world-wide exclusive access rights to OBJ’s technologies in the area of a beauty.
Negotiations commenced regarding the various financial, developmental and investment commitments by the FMCG company to OBJ’s technologies and considerable progress in these negotiations was achieved during the period.
"Not surprisingly, we like there to be strong robust IP or the opportunity to do that fairly quickly. Putting it simply, why should I pay for something that is not protected?" - Jeffrey Weedman - SVP P&G External Business Development
... Putting it simply, it is now protected, Mr Weedman ;)
- Forums
- ASX - By Stock
- WFL
- european dermaportation patent
european dermaportation patent, page-20
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable